NCT01679405终止1 期
Open-label, Uncontrolled, Multicenter Phase I/Ib Trial to Investigate Safety and Efficacy of BIBW 2992 and Standard Gemcitabine/Cisplatin in Chemo-naïve Patients With Advanced Biliary Tract Adenocarcinoma
Johannes Gutenberg University Mainz1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2012年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Number of Adverse Events
研究概览
简要总结
An open-label, uncontrolled, multicenter phase I/Ib trial to investigate safety and efficacy of BIBW 2992 added to the standard therapy of Gemcitabine/Cisplatin in chemo-naïve patients with advanced and/or metastatic adenocarcinoma of the biliary tract
详细描述
The primary objective is safety and toxicity, including maximum tolerated dose, of BIBW 2992 when given as add-on therapy to Gem/Cis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients aged ≥ 18 years
- •Signed and dated written informed consent,
- •Histologically confirmed adenocarcinoma of the gallbladder or intrahepatic bile ducts or extrahepatic bile ducts (metastasized) or histologically proven hepatic metastases of an earlier resected and histologically proven biliary tract cancer or a Klatskin tumour (hilar cholangiocarcinoma)
- •with pain and biliary obstruction controlled
- •adequate biliary drainage, no uncontrolled infection
- •ECOG Performance Status of 0-1
- •LFTs: bilirubin (total) ≤ 1.5 x ULN, ALT/ AST/ alkaline phosphatase ≤ 3 2.5 x ULN (≤ 5 x ULN if liver metastases are present)
- •No prior systemic treatment i) previous adjuvant chemotherapy is allowed (completed ≥ 6 months if containing Gemcitabine or platinum salts); ii) previous irradiation (external radiotherapy, brachytherapy, chemoembolization) and PDT are allowed, provided that there is still at least one unidimensionally measurable target lesion in an untreated area
- •Resolution of all side effects of prior surgical procedures to CTCAE grade ≤ 1 (except for the laboratory values specified below)
- •At least 4 weeks from any major surgery (at first dose of study drug)
- •Life expectancy of at least 12 weeks.
- •Cardiac left ventricular function with resting ejection fraction (LVEF) ≥ 50%
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of therapy:
- •Haemoglobin > 10.0 g/dl (=6.2 mmol/l), blood transfusion is allowed
- •Absolute neutrophil count (ANC) > 1,500/mm3 (=1.5x 109/L)
- •Platelet count ≥ 100,000/μl (=100x 109/L)
- •Total bilirubin ≤ 1.5 times the upper limit of normal
- •ALT and AST ≤ 2.5 x institutional upper limit of normal (in case of liver metastases: ALT and AST ≤ 5 x institutional upper limit of normal)
- •Prothrombin rate > 60% or INR < 1.5
- •Main exclusion criteria
- •Large surgery (except diagnostic biopsy) or smaller surgical procedures, external radiotherapy, brachytherapy, or PDT within 30 days prior to start of treatment.
- •Other tumor type than adenocarcinoma (e.g. leiomyosarcoma, lymphoma) or a second cancer except in patients with squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix which has been effectively treated.
- •History of acute cardiac disease: congestive heart failure > NYHA class 2; active CAD (MI more than 6 months prior to study entry is allowed);
- •Patients on immunosuppressant therapy or with known HIV infection
- •Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- •History of organ allograft
- •Pregnant or breast-feeding patients.
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation
- •Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- •Gastrointestinal (GI) tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease
- •History of pre-existing interstitial lung disease (ILD)
- •Patients with untreated or symptomatic brain metastases.
- •Persistent Grade 2 or greater neurotoxicity / neuropathy from any cause
排除标准
- 未提供
研究组 & 干预措施
Dose level 1 (Part A)
Experimental
30 mg BIBW 2992, Gemcitabin (1.000 mg/m² BSA i.v.)/Cisplatin (25 mg/m² BSA i.v.)
干预措施: BIBW 2992 (Drug)
Dose level -1 (Part A)
Experimental
30 mg BIBW 2992, Gemcitabin (800 mg/m² BSA i.v.)/Cisplatin (20 mg/m² BSA i.v.)
干预措施: BIBW 2992 (Drug)
结局指标
主要结局
Number of Adverse Events
时间窗: Treatment period: up to eight cycles (maximum 8 months). 12 months follow-up period.
In part A the maximum tolerated dose (MTD) of BIBW 2992 administered continuously to the standard therapy of Gemcitabine / Cisplatin (Gem/Cis) (administered together on day 1 and 8 of a three-week cycle) will be evaluated in a 2 step dose escalation. Safety and toxicity will be evaluated as described and considered primary for part B of the study.
次要结局
- Objective Response Rate(Treatment period: up to eight cycles (maximum 8 months).)
- Time to Progress (TTP)(Treatment period: up to eight cycles (maximum 8 months). 12 months follow-up period.)
- Overall Survival (OS)(Time from start of treatment to death due to any cause. Time to last observation will be used if a patient has not died and OS for the patient will be considered censored. Estimated time period: up to 76 weeks)
- Tumor Control Rate(Treatment period: up to eight cycles (maximum 8 months).)
研究者
PD Dr Markus Möhler
Principal Investigator
Johannes Gutenberg University Mainz
研究点 (1)
Loading locations...
相似试验
招募中
1 期
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionHCCNCT06560827CARsgen Therapeutics Co., Ltd.30
招募中
1 期
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic CancerPancreatic CancerNCT05911217CARsgen Therapeutics Co., Ltd.20
已完成
1 期
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic MelanomaMetastatic MelanomaNCT03875079Hoffmann-La Roche83
Unknown
1 期
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid TumorAdvanced Solid TumorNCT04719065CSPC ZhongQi Pharmaceutical Technology Co., Ltd.90
进行中（未招募）
1 期
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaB-cell Non-Hodgkin LymphomaNCT06251180Guangzhou Lupeng Pharmaceutical Company LTD.112